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Background
Glycosylation is an important posttranslational modifica-
tion of proteins influencing protein folding, stability and
regulation of the biological activity. The sialyl mojety
(sialic acid, 5-N-acetylneuramic acid) is usually exposed
at the terminal position of N-glycosylation and there-
fore, a major contributor to biological recognition and
ligand function, e.g. IgG featuring terminal sialic acids
were shown to induce less inflammatory response and
increased serum half-life.
The biosynthesis of sialyl conjugates is controlled by a
set of sugar-active enzymes including sialyltransferases
which are classified as ST3, ST6 and ST8 based on the
hydroxyl position of the glycosyl acceptor the Neu5Ac is
transferred to [1]. The ST6 family consists of 2 subfami-
lies, ST6Gal and ST6GalNAc. ST6Gal catalyzes the
transfer of Neu5Ac residues to the hydroxyl group in
C6 of a terminal galactose residue of type 2 disaccharide
(Galb1-4GlcNAc).
To our knowledge, the access to recombinant ST6Gal-
I for therapeutic applications is still limited due to low
expression and/or poor activity in various hosts (Pichia
pastoris, Spodoptera frugiperda and E. coli).
The present study describes the high-yield expression
of two variants of human beta-galactoside alpha-2,6 sia-
lyltransferase 1 (ST6Gal-I, EC 2.4.99.1; data base entry
P15907) by transient gene expression in HEK293 cells
with yields >100 mg/L featuring distinct mono- (G2
+1SA) as well as bi- (G2+2SA) sialylation activity.
Materials and methods
Two N-terminally truncated fragments of human
ST6Gal-I (delta89, residues 89-406, and delta108, resi-
dues 109-406) were designed for transient gene expres-
sion (TGE): Instead of the natural leader sequence and
N-terminal residues, both ST6Gal-I coding regions har-
bor the Erythropoietin (EPO) signal sequence in order
to ensure correct processing of the polypeptides by the
secretion machinery. Following cloning into pM1MT,
expression of the ST6Gal-I coding sequences is under
control of a hCMV promoter followed by an intron A.
Sialyltransferase assays: 1. Asialofetuin was used as
acceptor and CMP-9F-NANA as donor substrate. Enzy-
matic activity was determined by measuring the transfer
of 9F-NANA to asialofetuin. 2. Recombinant humanized
IgG1 and IgG4 monoclonal antibodies (mabs), charac-
terized as G2+0SA, as well as desialylated EPO were
used as targets in sialylation experiments (30 μg
enzyme/300 μg target protein). Both enzyme variants of
ST6Gal-I (delta89 and delta108) were used under identi-
cal reaction conditions and the sialylation status was
analyzed by mass spectrometry.
Results
In using the suspension-adapted human embryonic kid-
ney (HEK) 293-F cell line, a modified serum-free Free-
Style™ medium platform plus transfection by the 293-
Free™ reagent, we were able to install a TGE shaker
fermentation process with product yields of up to 200
mg/L culture supernatant. Both variants delta89 and
delta108 could be isolated to >98% purity by a simple
2-step purification protocol.
To our surprise, both variants show a distinct and dif-
ferent sialylation activity as shown by sialylation kinetics
of a IgG4 molecule (Figure 1).
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Recently, the crystal structure of the delta89 variant
could be determined as first human ST6Gal-I by SIRAS
phasing using an iodide soak as derivative I [2]: An
elongated glycan from a crystallographic neighbour
binds to the active site, mimicking a substrate complex.
An analysis of substrate interactions and comparison to
other sialyltransferases allows modelling of a Michaelis
complex and conclusions on the catalytic mechanism.
Due to their high expression rates and easy purifica-
tion, both recombinant variants (delta89 and delta108)
of human ST6Gal-I are available in large quantities and
high purity. Both variants are active with high molecular
weight substrates like monoclonal antibodies. To our
surprise, they show different performance in sialylation
experiments using with bi-antennary glycans such as
mabs as well as tetra-antennary glycans (data not
shown) as substrate. Under identical reaction conditions,
bi-sialylated glycans are obtained in using variant
delta89, whereas delta108 yields mono-sialylated glycans.
Our findings on variant delta108 are in contradiction
to previous studies [3] claiming that the conserved
QVWxKDS sequence, residues 94-100 of human
ST6Gal-I, being essential for its catalytic activity.
To our knowledge, these human ST6Gal-I variants are
the first enzymes available in large quantities and cur-
rently, recombinant alpha-2,3 sialyltransferase 1 (ST3Gal-
I) and beta-1,4 galactosyltransferase 2 (B4Gal-T2) are
developed in order to strengthen this enzyme portfolio.
Together with the already available donor substrates
(activated sugars), a complete set of reagents will be soon
available for the commercial glycoengineering of proteins.
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Figure 1 Left panel: Variant delta89 yields 88% G2+2SA sialylation. However, after prolonged incubation (24 hrs), the bi-sialylation is
reduced to a stable mono-sialylation product, presumably by a sialydase activity. Right panel: Variant delta108 yields 70% G2+1SA and 7% G2
+2SA sialylation.
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